1. Home
  2. ZURA

as 06-20-2025 3:44pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Founded: 2022 Country:
United States
United States
Employees: N/A City: LA JOLLA
Market Cap: 61.9M IPO Year: N/A
Target Price: $14.33 AVG Volume (30 days): 533.4K
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.72 EPS Growth: N/A
52 Week Low/High: $0.97 - $5.07 Next Earning Date: 08-08-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

ZURA Daily Stock ML Predictions

Share on Social Networks: